Extended indication Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with advanced N
Therapeutic value No estimate possible yet
Total cost 81,250,000.00
Registration phase Registered

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information